S&P 500
5.431,60 -2,14 (-0,04%) Nasdaq
17.688,88 +21,28 (+0,12%) NIKKEI 225
38.106,41 -708,15 (-1,82%) Dólar/Euro
1,0705 -0,0003 (-0,03%) Petróleo Brent
82,46 -0,16 (-0,19%) Bitcoin EUR
61.968,85 +215,01 (+0,35%)
Centessa Pharmaceuticals plc (CNTA)
Después del cierre:
Centessa Pharmaceuticals plc
1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
https://www.centessa.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 77
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | CEO & Director | 1,04M | N/A | 1976 |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer | 710,3k | N/A | 1968 |
| Dr. Antoine Yver M.D., M.Sc. | Executive VP & Chairman of Development | 773,14k | N/A | 1958 |
| Ms. Tia L. Bush | Chief Technology & Quality Officer | N/A | N/A | 1971 |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary | N/A | N/A | 1981 |
| Ms. Karen M. Anderson | Chief People Officer | N/A | N/A | 1968 |
Descripción
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Centessa Pharmaceuticals plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
